Lafutidine

Summary

Lafutidine (CHEMBL1742461) is a phase-3 clinical-stage small molecule (ATC A02BA08); indicated across 4 conditions including gastroesophageal reflux disease and peptic ulcer disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: A02BA08
• Indications: 4 conditions
• Clinical trials: 6
• Chemistry: 431.6 Da · C22H29N3O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1742461
Name	Lafutidine
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	5282136
ATC	A02BA08
Molecular formula	C22H29N3O4S
Molecular weight	431.6
InChIKey	KMZQAVXSMUKBPD-DJWKRKHSSA-N

SMILES: C1CCN(CC1)CC2=CC(=NC=C2)OC/C=C\CNC(=O)CS(=O)CC3=CC=CO3

IUPAC name: 2-(furan-2-ylmethylsulfinyl)-N-[(Z)-4-[[4-(piperidin-1-ylmethyl)-2-pyridinyl]oxy]but-2-enyl]acetamide

Also known as: Lafutidina, Lafutidine, SID144205732, SID170465978, LAFUTIDINE, lafutidine

Patent coverage: 742 distinct patent families (2,370 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,345 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Alpha-2C adrenergic receptor.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRA2C	5.58	AC50	2600	nM	CHEMBL_ACT_25148526

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
gastroesophageal reflux disease	3	MONDO:0007186	EFO:0003948
peptic ulcer disease	3	MONDO:0004247	HP:0004398
chronic gastritis	1	MONDO:0005001	EFO:0000337
gastric ulcer	1	MONDO:0001126	EFO:0009454

Clinical trials

Total trials: 6.

Phase distribution

Phase	Trials
PHASE1	3
PHASE3	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00229424	PHASE3	COMPLETED	Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -
NCT01499368	PHASE3	COMPLETED	A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients
NCT02581696	PHASE1	COMPLETED	The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers
NCT02658864	PHASE1	COMPLETED	Pharmacokinetic Properties and Effect of Food on Pharmacokinetic Properties of the Oral Lafutidine Tablets
NCT02759224	PHASE1	COMPLETED	A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet
NCT02555852	Not specified	COMPLETED	Proton Pump Inhibitors and Risk of Community-acquired Pneumonia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).